Cargando…
P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol
INTRODUCTION: Solriamfetol (Sunosi) is a dopamine/norepinephrine reuptake inhibitor approved (EU/US) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnoea (OSA) (37.5–150 mg/day). This study characterised real-world dosing and titration wit...
Autores principales: | Thorpy, M, Hyman, D, Parks, G, Chen, A, Foley, C, Ito, D, Singh, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108998/ http://dx.doi.org/10.1093/sleepadvances/zpab014.189 |
Ejemplares similares
-
P147 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with obstructive sleep apnoea (OSA) and prescriber rationale for starting treatment with solriamfetol
por: Singh, H, et al.
Publicado: (2021) -
Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario
por: Singh, Haramandeep, et al.
Publicado: (2022) -
A randomized study of solriamfetol for excessive sleepiness in narcolepsy
por: Thorpy, Michael J., et al.
Publicado: (2019) -
Solriamfetol for the Use of Narcolepsy: A Systematic Review
por: Iturburu, Alisson, et al.
Publicado: (2022) -
Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial
por: Vinckenbosch, Frederick, et al.
Publicado: (2022)